Veru says press release available on 2026 Obesity & Weight Loss Drug Development Summit presentation

Veru Inc

Veru Inc

VERU

0.00
  • Veru posted an investor update on its planned presentations at the 2026 Obesity & Weight Loss Drug Development Summit in Boston, July 14-16.
  • CEO Mitchell Steiner is scheduled to present July 15 on combining GLP-1 drugs with SARMs to limit muscle loss in older patients.
  • CSO Gary Barnette is scheduled to speak July 14 in a workshop focused on obesity trial endpoints beyond BMI.
  • Release highlighted the Phase 2b PLATEAU study of enobosarm with semaglutide, with interim DXA analysis targeted for Q1 2027.
  • Final topline data from PLATEAU is expected in Q4 2027; summit details at .


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veru Inc. published the original content used to generate this news brief on July 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.